To elucidate the association of human papillomavirus (HPV) and Epstein-Barr virus (EBV) with carcinogenesis of the esophagus, 41 surgically resected specimens and 12 cell lines of esophageal squamous cell carcinoma were examined for the presence of HPV DNA and EBV DNA by polymerase chain reaction using primers for the E6 regions of HPV-16 and -18 and for the EBNA 1 region of EBV. We designed the reaction condition to amplify HPV and EBV DNA specifically and detected by gel electrophoresis. In ethidium bromide staining, no band was detected either for the HPV E6 region or for the EBV EBNA 1 gene in any of the surgically resected specimens and the cell lines, although the HPV sequence was detectable by Southern blot hybridization, which is a more sensitive detection method than staining; three out of 41 surgically resected specimens were positive for HPV-18 by Southern blot hybridization of polymerase chain reaction products. However, the number of viral genomes has been estimated as lower than 1 × 10 -3 copies per cell based on the intensity of the hybridization signals. Moreover, the DNA samples extracted from the corresponding non-cancerous esophageal mucosa were also positive for HPV-18, and the intensities of the hybridization signals were almost the same as those of the tumors. The results of our study indicate that HPV-16, HPV-18 and EBV are not generally associated with esophageal carcinogenesis.
INTRODUCTION
The recent interest in human papillomavirus (HPV) and its association with cervical squamous cell carcinoma (SCC) (1) (2) (3) (4) has prompted the investigation for its possible etiological role in cancers at other body sites. In lesions of the skin (5), oral cavity (6), tongue (7) , larynx (8) and lung (9) , the presence of HPV was investigated initially by DNA hybridization techniques and recently by polymerase chain reaction (PCR).
HPV infection of the esophagus was first suggested by morphologic studies showing HPV-induced cytopathic changes (10) and later by immunohistochemical techniques demonstrating the presence of HPV antigens (11, 12) . The presence of the HPV genome in SCC of the esophagus was demonstrated by DNA hybridization techniques and/or PCR. However, the HPV detection rates vary considerably among different authors, ranging from 0% to 49% (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . In Japan, Furihata et al. (13) reported that 33.8% of patients with esophageal SCC were positive for HPV DNA by in situ hybridization and Toh et al. (14) reported a prevalence of 6.7% by PCR. It is important to establish whether HPV DNA is demonstrated in Japanese esophageal carcinoma and whether this virus plays a role in the etiology of the disease. In this study we used the PCR technique to detect HPV-16 and HPV-18 DNAs with primers amplifying a portion of the E6 region. The specific HPV DNA sequences amplified by PCR were subsequently confirmed by Southern blot hybridization with the HPV-specific probes.
The Epstein-Barr virus (EBV) was first identified in 1964 in cultured Burkitt's lymphoma cells (23) and has since been implicated in a variety of benign and malignant lymphoproliferative diseases. The association of EBV with undifferentiated nasopharyngeal carcinoma has been well documented (24, 25) . However, it remains controversial whether the nasopharyngeal SCC are also EBV-associated. Recently, the involvement of EBV has been demonstrated in gastric adenocarcinoma of various grades of differentiation without prominent lymphoid infiltration (26, 27) .
Thus it is of interest to determine whether EBV is involved in carcinoma of the esophagus, which is located between the nasopharynx and stomach. In this study we investigated the presence of EBV in squamous cell carcinoma of the esophagus by PCR.
MATERIALS AND METHODS

EXTRACTION OF DNA FROM SURGICAL SPECIMENS AND CULTURED CELL LINES
The surgically resected specimens of esophageal carcinoma were obtained from the National Cancer Center Hospital at the time of surgery, snap-frozen in liquid nitrogen immediately after resection, and stored at -80_C until DNA extraction. Human esophageal carcinoma cell lines TE1-TE6 and TE8-TE13 were kindly provided by Dr. T. Nishihira (Second Department of Surgery, Faculty of Medicine, Tohoku University). Each cell line was established from SCC and was maintained in RPMI-1640 with 7% fetal bovine serum. Human cervical cancer cell lines SKG-IIIa and HeLa were maintained in Ham's F12 medium with 10% fetal bovine serum and in Eagle's minimum essential medium with 10% calf serum respectively. SKG-IIIa cells and HeLa cells contain approximately one copy of HPV-16 DNA and 10-20 copies of HPV-18 sequence per haploid genome respectively (2) .
DNA was extracted as previously described (28) from the surgical specimens and cell lines. All the DNA samples were suitable for PCR analysis, because the 170 bp (base pair) fragment of the EXP1 gene, which is a gene identified on chromosome 11q13, about 120kb apart from the HST1 gene (29) , was successfully amplified (data not shown). The EXP1 primers are: P40, 5′-AGCATTTGTGCCTGAAGCTGC-3′ and P9, 5′-TGAAACCTCTCATCCGCCATCACGA-3′.
PCR reaction was performed in a 50 µl volume with 400 ng of template DNAs, 1x PCR Buffer, 10 mM of each deoxynucleotide triphosphate, 0.5 µg of each primer and 2.5 units of Taq-polymerase. The conditions for PCR analyses were as follows: 94_C for 10 min (1 cycle); 94_C for 1 min, 60_C for 2 min, 72_C for 3 min (30 cycles); 72_C for 10 min (1 cycle). After amplification of PCR, 10 µl (corresponding to 1/5 volume of the reaction mixture) was subjected to gel electrophoresis on a 3.5% NuSieve 3:1 agarose gel and stained with ethidium bromide. In ethidium bromide staining, the amplified 170 bp fragments corresponding to a DNA fragment of EXP1 used as an internal control were seen in all of the surgical specimens and the cell lines (data not shown), confirming that all DNA samples were suitable for PCR analysis.
PCR ANALYSIS AND SOUTHERN BLOT HYBRIDIZATION FOR HPV-16 AND HPV-18 DNA
Oligonucleotide primers were synthesized by a 392 DNA/RNA synthesizer (Perkin Elmer Co., Connecticut) according to published sequences (30) . Sequences of primers for amplification of the E6 regions of HPV-16 and HPV-18 are as follows:
p16F, 5′-AAGGGCGTAACCGAAATCGGT-3′; p16R, 5′-GTTTGCAGCTCTGTGCATA-3′; p18F, 5′-AAGGGAGTAACCGAAAACGGT-3′; p18R, 5′-GTGTTCAGTTCCGTGCACA-3′. p16F and p18F correspond to the E6 sense sequence of HPV-16 and HPV-18 respectively. p16R and p18R correspond to the E6 antisense sequence of HPV-16 and HPV-18 respectively. Each PCR reaction mixture (100 µl) contained 600 ng of template DNA, 1x PCR Buffer (10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl 2 , 0.001% (W/V) gelatin), 10 mM of each deoxynucleotide triphosphate, 0.15 µg of each primer and 2.0 units of Taq-polymerase. The PCR-cycling reactions were performed on a Perkin-Elmer Cetus (Norwalk, CT) DNA thermal cycler. After one cycle of denaturation at 94_C for 10 min, 30 cycles of 94_C for 1 min, 55_C for 2 min and 72_C for 2 min were carried out followed by extension at 72_C for 10 min. All experiments were performed in parallel with positive controls (SKG-IIIa for HPV-16 and HeLa for HPV-18) and negative controls (HeLa for HPV-16 and SKG-IIIa for HPV-18).
After amplification of PCR, 10 µl (1/10 volume) of the reaction mixture was subjected to gel electrophoresis on a 3.5% NuSieve 3:1 agarose gel and stained with ethidium bromide. DNA was transferred to the Hybond-N (Amersham International plc, Buckinghamshire, UK) membrane filter. Hybridization was performed at 42_C for 8-12 h in a hybridization solution (50% formamide, 0.1 M PIPES-NaOH, pH 6.8, 0.65 M NaCl, 5x Denhardt's solution, 5 mM EDTA, 0.1% SDS, 10% Dextran sulfate, 100 µg/ml denatured salmon testis DNA and 32 P-labeled HPV-16 or HPV-18 probe at 1 10 6 c.p.m./ml). After hybridization, the filters were washed and exposed at -80_C to Kodak XAR-5 film with an intensifying screen for 1 to 4 days.
SENSITIVITY OF PCR FOR AMPLIFYING HPV-16 AND HPV-18 DNA
To define the sensitivity of the PCR, DNA from SKG-IIIa cells or HeLa cells was serially diluted with salmon testis DNA and was subjected to PCR analysis for HPV-16 or HPV-18. After amplification by PCR, the reaction mixture was electrophoresed, blotted and hybridized with 32 P-labeled HPV-16 or HPV-18 DNA as a probe .
PCR ANALYSIS FOR EBV DNA
Sequences of EBV primers, from published data (31) are as follows:
The primers amplify and detect an 80-base pair region of the EBNA1 gene. Each PCR reaction mixture (100 µl) contained 600 ng of template DNAs, 1x PCR Buffer, 10 mM of each deoxynucleotide triphosphate, 0.25 µg of each primer, 1.0 unit of Perfect Match (Stratagene, California) and 3.0 units of Taq-polymerase. The conditions for PCR analyses were as follows: 94_C for 10 min (1 cycle); 95_C for 45 sec, 60_C for 45 sec, 72_C for 60 sec (35 cycles); 72_C for 10 min (1 cycle). All experiments were performed in parallel with pDR 2 (Clontech Laboratories, Inc., California), which is the vector containing the EBV EBNA 1 sequence, as a positive control, and with a negative control in which PCR reaction was performed without a template DNA. After PCR amplification, 10 µl of the reaction mixture was subjected to gel electrophoresis on a 3.5% NuSieve 3:1 agarose gel and stained with ethidium bromide.
RESULTS
DETECTION OF HPV DNAS
The PCR products amplified with the two sets of primers specific for HPV-16 or HPV-18 DNAs were observed as a specific band of the expected size (140 bp) in the positive controls, SKG-IIIa for HPV-16 and HeLa for HPV-18 ( Fig. 1) . No band was detected in DNAs from HeLa and SKG-IIIa cells which were used as negative controls for HPV-16 and HPV-18 DNA, respectively.
Ethidium bromide staining of the gel revealed no detectable band for any of the 41 surgical specimens or the 12 cell lines. Moreover, by Southern blot hybridization of PCR products, no HPV-16 genome was detectable in any of the surgical specimens or the cell lines (data not shown). Although all of the 12 cell lines were negative, three out of 41 surgical specimens were positive for HPV-18 DNA. The intensity of their hybridization signals was weaker than that of 1/50 000 diluted HeLa cell DNA. In the DNA samples extracted from the corresponding non-cancerous esophageal mucosae of the same patients, an HPV-18 DNA fragment was detected with almost the same intensity of hybridization signals as that of the tumor counterparts (Fig. 1) .
Comparison of the intensities of the serially diluted DNA fragments demonstrates that the method we used could detect, in PCR products, 0.1 copies per haploid genome by ethidium bromide staining and 10 -3 copies per haploid genome by Southern blot hybridization, of both HPV-16 and HPV-18 DNAs (Fig. 2 and data not shown) .
DETECTION OF EBV DNA
A specific band of the expected size of 80 bp should be detected in the PCR products amplified with two primers specific for EBV DNA, if EBV EBNA 1 gene is present in a DNA sample. No EBV EBNA1 specific DNA could be detected by ethidium bromide staining in any of the 41 surgical specimens or the 12 cell lines (Fig. 3) . Kulski et al. (32) detected HPV DNA in esophageal SCC (four of 10 cases) in Western Australia by filter in situ hybridization. However, Loke et al. (15) were unable to detect HPV genome in 37 cases of esophageal SCC in Hong Kong by slot blot hybridization or in situ hybridization. In France, one of 12 esophageal SCC was positive for HPV-18 DNA by in situ hybridization and three others were positive by dot blot hybridization (16) . In the Linxian district of China, the high-incidence area for esophageal carcinoma, 71 (19.6%) of 363 patients with esophageal SCC were shown to have HPV DNA in their cancer cells by in situ hybridization (17) . In Japan, 24 (33.8%) of 71 patients with esophageal SCC were positive for HPV DNA by in situ hybridization (13) . Of the 24 cases, 10 were HPV-16 and the others were HPV-18.
DISCUSSION
Among the PCR-based studies for the HPV-DNA detection, 25 out of 51 (49.0%) biopsy specimens in esophageal precancerous lesions and squamous cell carcinomas have been reported as being positive in the Linxian district of China (33) . The specific HPV DNA sequences amplified by PCR were subsequently confirmed by Southern blot hybridization with specific HPV probes. Togawa et al. (18) identified HPV DNA in 14% (10/72) of esophageal squamous cell carcinomas from different regions of the world by a radioactive nested PCR /restriction fragment length polymorphism analysis. By contrast, Kiyabu et al. (19) detected neither HPV-16 nor HPV-18 DNA in 13 esophageal carcinomas in North American patients, using PCR with primers which amplify the E6 of both HPV-16 and HPV-18. Smits et al. (20) detected HPV DNA in none of the 61 esophageal squamous cell carcinomas by multiple broad spectrum PCR. Among 14 patients with esophageal SCC in South Africa, 6 (42.9%) were positive for HPV DNA in tumor biopsies by PCR with primers which amplify the L1 gene of a wide range of HPVs (21). Toh et al. (14) in Japan showed by PCR that three (6.7%) of 45 biopsy samples of esophageal SCC contained HPV-16 or HPV-18 DNA. In this study, primers for PCR were firstly consensus primers for the simultaneous amplification of the E6-E7 regions for cancerassociated HPV types and secondarily type-specific primers for the E7 regions. In the latter three reports, confirmation by Southern blot hybridization of PCR products has not been performed.
Marked variations in the prevalence of esophageal HPV infections have been reported by different authors. This difference might be due to the difference in the methods used. We have used PCR analysis coupled with Southern blot hybridization to detect the E6 region of the HPV-16 or HPV-18 genome, with adequate positive and negative control. The sensitivity of our PCR detection system of the HPV genome was 0.1 copies per haploid genome by ethidium bromide staining and 10 -3 copies per haploid genome by Southern blot hybridization of PCR products.
In the present series, three out of 41 surgical specimens were positive for HPV-18 DNA by Southern blot hybridization of PCR products. However, the intensity of hybridization signals in these cases was weaker than that of 1/50 000 diluted HeLa cell DNA, which carries 10-50 integrated copies of HPV-18 DNA per haploid genome (2) , indicating that the number of viral genomes in those samples is probably lower than 1 10 -3 copies per haploid genome. The possibility of the specific presence of the HPV genome in a clonal population of the tumor cells is quite unlikely. Moreover, HPV-18 was also positive in DNA extracted from their normal esophageal epithelium and the intensity of the hybridization signals was almost the same as that of the tumor cell. Therefore we presume that HPV is present in fewer than one in 10 3 cells in the cancerous as well as non-cancerous portion of the esophagus of those patients as a fortuitous parasite of the organ.
While there is a report indicating 33.8% positive for HPV DNA by in situ hybridization in Japan (13), this has not been confirmed in other studies. The reason for the discrepancy remains to be elucidated, but it could be due to a difference in the methods employed. It is also possible that there may be a geographic variation in the prevalence of HPV infection in Japan.
Recently, an association of EBV with epithelial malignancies without prominent lymphoid infiltration has been demonstrated, especially in gastric adenocarcinoma (26) . Very little information is available yet in the literature with respect to the possible association of EBV with another upper digestive tract cancer, SCC of the esophagus. Niedobitek et al. (25) have demonstrated the absence of detectable EBV-DNA in any of the eight squamous cell NPCs, 26 SCCs of the tonsils and 14 cervical cancers examined. We have demonstrated the absence of detectable EBV-DNA in all of the 41 surgical specimens and 12 cell lines of the SCCs of the esophagus.
Our PCR analyses detected no specific association of HPV or EBV genome with esophageal SCCs. The present results strongly suggest that HPV-16, HPV-18 and EBV do not play any significant role in the development of esophageal carcinomas.
